251 related articles for article (PubMed ID: 28292939)
1. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
[TBL] [Abstract][Full Text] [Related]
2. Effects of FasL expression in oral squamous cell cancer.
Fang L; Sun L; Hu FF; Chen QE
Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
[TBL] [Abstract][Full Text] [Related]
3. Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Zepeda-Nuño JS; Guerrero-Velázquez C; Del Toro-Arreola S; Vega-Magaña N; Ángeles-Sánchez J; Haramati J; Pereira-Suárez AL; Bueno-Topete MR
Pathol Oncol Res; 2017 Apr; 23(2):345-353. PubMed ID: 27628319
[TBL] [Abstract][Full Text] [Related]
4. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma.
Das SN; Khare P; Singh MK; Sharma SC
Indian J Med Res; 2011 Jul; 134(1):54-60. PubMed ID: 21808135
[TBL] [Abstract][Full Text] [Related]
5. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity.
de Carvalho-Neto PB; dos Santos M; de Carvalho MB; Mercante AM; dos Santos VP; Severino P; Tajara EH; Louro ID; da Silva-Conforti AM
PLoS One; 2013; 8(7):e69024. PubMed ID: 23894399
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma.
Loro LL; Vintermyr OK; Johannessen AC; Liavaag PG; Jonsson R
J Oral Pathol Med; 1999 Feb; 28(2):82-7. PubMed ID: 9950255
[TBL] [Abstract][Full Text] [Related]
7. A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.
Cai Y; Wang F; Liu Q; Li Z; Li D; Sun Z
Invest New Drugs; 2019 Oct; 37(5):799-809. PubMed ID: 30368626
[TBL] [Abstract][Full Text] [Related]
8. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
9. FAS ligand expression in inflammatory infiltrate lymphoid cells as a prognostic marker in oral squamous cell carcinoma.
Peterle GT; Santos M; Mendes SO; Carvalho-Neto PB; Maia LL; Stur E; Agostini LP; Silva CV; Trivilin LO; Nunes FD; Carvalho MB; Tajara EH; Louro ID; Silva-Conforti AM
Genet Mol Res; 2015 Sep; 14(3):11145-53. PubMed ID: 26400345
[TBL] [Abstract][Full Text] [Related]
10. Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma.
Fujieda S; Sunaga H; Tsuzuki H; Fan GK; Ito T; Sugimoto C; Saito H
Cancer Lett; 2000 Dec; 161(1):73-81. PubMed ID: 11078915
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
12. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
[TBL] [Abstract][Full Text] [Related]
13. CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity.
Jodo S; Hohlbaum AM; Xiao S; Chan D; Strehlow D; Sherr DH; Marshak-Rothstein A; Ju ST
J Immunol; 2000 Nov; 165(10):5487-94. PubMed ID: 11067901
[TBL] [Abstract][Full Text] [Related]
14. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
15. Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.
Nagai K; Nakahata S; Shimosaki S; Tamura T; Kondo Y; Baba T; Taki T; Taniwaki M; Kurosawa G; Sudo Y; Okada S; Sakoda S; Morishita K
Cancer Med; 2014 Aug; 3(4):1085-99. PubMed ID: 24890018
[TBL] [Abstract][Full Text] [Related]
16. Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis.
Rigberg DA; Centeno J; Kim FS; Ke B; Swenson K; Maggard M; McFadden DW
J Surg Oncol; 1999 Jun; 71(2):91-6. PubMed ID: 10389864
[TBL] [Abstract][Full Text] [Related]
17. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)?
Sproll KC; Balló H; Hoffmann TK; Scheckenbach K; Koldovsky U; Balz V; Hafner D; Ramp U; Bier H
Oral Oncol; 2009 Jan; 45(1):69-84. PubMed ID: 18620901
[TBL] [Abstract][Full Text] [Related]
19. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Slit-Robo signal on apoptosis of oral cancer cell line Tb].
Ma YG; Wang LJ; Han B; Zhang J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Apr; 41(4):232-5. PubMed ID: 16784591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
